Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Public Venture Capital for Israel's Biotech Industry

This article was originally published in Start Up

Executive Summary

Israeli biotech is hot -- lots of ideas and lots of entrepreneurs. But the industry is chronically short of management and venture money. For the latter, companies have turned to Israel's recently deregulated stock market.

You may also be interested in...

Xenia's Public-Private Blend Fosters Early-Stage Medtech

Israel's Xenia Venture Capital is an early-stage technology incubator with an unusual model for getting medical technologies out of the nest and on the wing.

The Existential Dilemma of Israeli Biotech

Israel's biotech industry -- a scientific and entrepreneurial dynamo but starved for capital, infrastructure, and managerial experience -- is facing its existential dilemma. For some, the industry's current problems are merely a reflection of economic Darwinism; others are planning more radical financing innovations. Meanwhile, the relatively rich in Israel, some of the incubators like Clal, and especially the country's biggest company, Teva, are soaking up the available opportunities for relatively little money.

Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q3 2007

In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for July-September 2007. Our data are derived from Windhover's Strategic Transactions Database.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts